Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended March 31, 2026
RELIGARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Investment Company peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Religare Enterprises reported a standalone net loss of Rs. 3,379.87 lakhs for FY2026, slightly improved from Rs. 3,754.28 lakhs loss in FY2025. Total income declined sharply to Rs. 1,644.09 lakhs from Rs. 4,182.01 lakhs in the previous year, a drop of about 61%. Finance costs reduced significantly from Rs. 1,538.51 lakhs to Rs. 448.43 lakhs. The company received Rs. 41,000 lakhs from warrant conversions and invested Rs. 25,610.35 lakhs in subsidiary Care Health Insurance. Auditors issued an un-modified (clean) opinion but drew emphasis on ongoing income tax litigation with a demand of Rs. 10,853 lakhs. The board also approved a demerger scheme to transfer financial services business to Religare Finvest Limited.
The company continues to operate at a loss with significantly reduced revenue. Shareholders should note the ongoing tax litigations, governance review in progress, and RBI dividend restriction. The demerger proposal may create future structural changes. Cash position weakened with only Rs. 209.96 lakhs at year-end.